Symbicort is a combination inhaler used to control asthma and to maintain airflow in people with chronic obstructive ...

namely maintenance treatment for asthma and chronic obstructive pulmonary disease (COPD). Symbicort brought in worldwide sales of $2.7 billion last year, with $1.1 billion of that coming from the ...

and Symbicort (budesonide + formoterol fumarate dihydrate; AstraZeneca), which are ICS–LABA combinations, are other popular COPD drugs. A major limitation with the current corticosteroid therapy ...

Notably, the company had already taken steps to make SYMBICORT more accessible by substantially ... the lives of those ...

Symbicort was first FDA-approved in 2006 as a treatment for asthma, followed by an extension to its label covering COPD in 2009. A further approval in 2017 in childhood asthma has helped the drug ...